» Articles » PMID: 37763805

Exploring the Dynamic Role of Bacterial Etiology in Complicated Urinary Tract Infections

Overview
Publisher MDPI
Specialty General Medicine
Date 2023 Sep 28
PMID 37763805
Authors
Affiliations
Soon will be listed here.
Abstract

. Numerous studies have been conducted to explore the epidemiological characteristics of urinary tract infections (UTI) and sepsis. However, there is still a lack of relevant bacteriological features and prognostic information regarding urosepsis based on bacteriological etiology. The current study aims to evaluate the bacterial etiology of complicated UTI (cUTI) and bacterial resistance to antibiotics and whether they present an intrinsic risk of developing urosepsis. . A retrospective study was performed that included 102 patients who were diagnosed with cUTI and admitted to the urology department of the "Sfântul Apostol Andrei" County Emergency Clinical Hospital (GCH) from September 2019 to May 2022. A considerable number of patients, n = 41 (40.2%), were diagnosed with multi drug-resistant (MDR) infection. () was identified as the prevailing pathogen, accounting for 51 patients. manifested itself as the subsequent causative agent in 27 instances. The presence of spp. infection was documented in 13 patients, whereas emerged as the etiological perpetrator in the clinical context of 8 patients. The current study found a substantial prevalence of resistance to first-line antibiotics. The overall resistance rate was 74.5% for penicillin, 58.82% for trimethoprim-sulfamethoxazole and 49% for fluoroquinolones; cephalosporin resistance displayed an inverse correlation with antibiotic generation with fourth-generation cephalosporins exhibiting a resistance rate of 24.5%, and first-generation cephalosporins demonstrating a resistance rate of 35.29%. . Age, comorbidities and indwelling urinary catheters are risk factors for developing MDR infections. While the intrinsic characteristics of the causative bacterial agent in cUTI may not be a risk factor for developing urosepsis, they can contribute to increased mortality risk. For empiric antibiotic treatment in patients with cUTI who are at a high risk of developing urosepsis and experiencing a potentially unfavorable clinical course, broad-spectrum antibiotic therapy is recommended. This may include antibiotics, such as amikacin, tigecycline, carbapenems and piperacillin-tazobactam.

Citing Articles

Bacterial Infections, Trends, and Resistance Patterns in the Time of the COVID-19 Pandemic in Romania-A Systematic Review.

Vulcanescu D, Bagiu I, Avram C, Oprisoni L, Tanasescu S, Sorescu T Antibiotics (Basel). 2025; 13(12.

PMID: 39766609 PMC: 11726834. DOI: 10.3390/antibiotics13121219.


Unravelling the Antimicrobial, Antibiofilm, Suppressing () and Virulence Genes, Anti-Inflammatory and Antioxidant Potential of Biosynthesized Silver Nanoparticles.

Mekky A, Abdelaziz A, Youssef F, Elaskary S, Shoun A, Alwaleed E Medicina (Kaunas). 2024; 60(3).

PMID: 38541241 PMC: 10972527. DOI: 10.3390/medicina60030515.


Novel Antimicrobial Approaches to Combat Bacterial Biofilms Associated with Urinary Tract Infections.

Mancuso G, Trinchera M, Midiri A, Zummo S, Vitale G, Biondo C Antibiotics (Basel). 2024; 13(2).

PMID: 38391540 PMC: 10886225. DOI: 10.3390/antibiotics13020154.

References
1.
Jiang Y, Li J, Zhang Y, Hu X, Zhang X, Shang X . Clinical Situations of Bacteriology and Prognosis in Patients with Urosepsis. Biomed Res Int. 2019; 2019:3080827. PMC: 6381567. DOI: 10.1155/2019/3080827. View

2.
Bischoff S, Walter T, Gerigk M, Ebert M, Vogelmann R . Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department. BMC Infect Dis. 2018; 18(1):56. PMC: 5787273. DOI: 10.1186/s12879-018-2960-9. View

3.
Chen Y, Ko W, Hsueh P . Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections. Expert Opin Pharmacother. 2013; 14(5):587-96. DOI: 10.1517/14656566.2013.778827. View

4.
Vazquez-Guillamet C, Scolari M, Zilberberg M, Shorr A, Micek S, Kollef M . Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock. Crit Care Med. 2014; 42(11):2342-9. DOI: 10.1097/CCM.0000000000000516. View

5.
Zilberberg M, Shorr A, Micek S, Vazquez-Guillamet C, Kollef M . Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014; 18(6):596. PMC: 4264255. DOI: 10.1186/s13054-014-0596-8. View